Suratadenoturev clinical trials
Also written OBP-301 and Telomelysin.
How each study uses suratadenoturev is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the suratadenoturev studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 6
Weill Medical College of Cornell University (3) · Oncolys BioPharma Inc (2) · NRG Oncology (1) · Toshihiko Doi (1) · Syneos Health (1)
Studies
Open first, then newest update. How each study uses suratadenoturev is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06340711Written as OBP-301
- Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for SurgeryActive, not recruitingPhase 1NRG OncologyNCT04391049Written as Telomerase-specific Type 5 Adenovirus OBP-301
- Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaCompletedPhase 2Weill Medical College of Cornell UniversityNCT03921021Written as Telomelysin
- Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive DiseaseTerminatedPhase 2Weill Medical College of Cornell UniversityNCT04685499Written as OBP-301
- Special Combination of OBP-301 and PembrolizumabCompletedPhase 1Toshihiko DoiNCT03172819Written as OBP-301
- Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic MelanomaStatus unknownPhase 2Syneos HealthNCT03190824Written as OBP-301
- A Study of OBP-301 With Radiation Therapy in Patients With Esophageal CancerStatus unknownPhase 1Oncolys BioPharma IncNCT03213054Written as OBP-301
- Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular CarcinomaStatus unknownPhase 1Oncolys BioPharma IncNCT02293850Written as OBP-301
Codes
What other systems call suratadenoturev · ClinicalTrials.gg INT016596
- UNII (FDA) FV0JG1SX76SURATADENOTUREVOne source FDA
- NCI Thesaurus C119617SuratadenoturevOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FV0JG1SX76 | SURATADENOTUREV | One source FDA |
| NCI Thesaurus | C119617 | Suratadenoturev | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.